A current monitoring of the Austrian Institute for Health Technology Assessment (AIHTA) shows that the member companies of PHARMIG have disclosed their financial contributions to patient initiatives significantly more often in 2021 than in 2019. „However, there is still a lack of transparency on the part of the patient organisations and thus a lack of awareness of the problem,“ criticises Claudia Wild, managing director of AIHTA.